XML 78 R50.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)
12 Months Ended
Jul. 01, 2013
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Sep. 23, 2014
Dec. 31, 2012
Fair Value of Financial Instruments [Line Items]            
Cash and cash equivalents   $ 59,074,000 $ 120,841,000 $ 70,790,000   $ 61,840,000
Cash equivalents, money market funds   55,800,000 118,500,000      
Transfers of assets between fair value measurement   0 0 0    
Transfers of liabilities between fair value measurement   0 0 0    
Property and equipment, net   48,749,000 192,127,000      
Property and equipment impairment   140,412,000 0 $ 0    
Sanofi-Aventis Deutschland GmbH            
Fair Value of Financial Instruments [Line Items]            
Carrying value   44,500,000 3,000,000      
Estimated fair value   36,500,000 3,000,000      
Senior convertible notes due August 15, 2015            
Fair Value of Financial Instruments [Line Items]            
Carrying value     99,355,000      
Senior convertible notes due August 15, 2015 | Convertible Debt Securities            
Fair Value of Financial Instruments [Line Items]            
Carrying value     99,400,000      
Estimated fair value     $ 102,900,000      
Senior convertible notes due August 15, 2018            
Fair Value of Financial Instruments [Line Items]            
Carrying value   27,613,000        
Senior convertible notes due August 15, 2018 | Convertible Debt Securities            
Fair Value of Financial Instruments [Line Items]            
Carrying value   27,600,000        
Estimated fair value   21,300,000        
License and Collaboration Agreement with Sanofi            
Fair Value of Financial Instruments [Line Items]            
Maximum secured loan facility         $ 175,000,000  
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH            
Fair Value of Financial Instruments [Line Items]            
Maximum secured loan facility   175,000,000        
Carrying value   44,500,000        
Estimated fair value   36,500,000        
Reported Value Measurement            
Fair Value of Financial Instruments [Line Items]            
Property and equipment, net   189,200,000        
Milestone Rights Liability | Deerfield | Maximum            
Fair Value of Financial Instruments [Line Items]            
Contingent liability for milestone payments $ 90,000,000          
Milestone Rights Liability | Senior convertible notes due December 31, 2019 | Deerfield            
Fair Value of Financial Instruments [Line Items]            
Market discount rate 17.50%          
Long term liability $ 13,100,000 8,900,000        
Fair Value, Inputs, Level 3            
Fair Value of Financial Instruments [Line Items]            
Property, plant, and equipment, fair value   $ 48,800,000        
Fair Value, Inputs, Level 3 | License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH            
Fair Value of Financial Instruments [Line Items]            
Market discount rate   11.00%        
Fair Value, Inputs, Level 3 | Milestone Rights Liability            
Fair Value of Financial Instruments [Line Items]            
Fair value of Milestone Rights   $ 14,400,000        
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019            
Fair Value of Financial Instruments [Line Items]            
Market discount rate   12.00%        
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability            
Fair Value of Financial Instruments [Line Items]            
Market discount rate   15.00%        
Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | Senior convertible notes due August 15, 2015 | Convertible Debt Securities            
Fair Value of Financial Instruments [Line Items]            
Fair value assumption, stock price volatility   55.00%        
Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | Senior convertible notes due August 15, 2018 | Convertible Debt Securities            
Fair Value of Financial Instruments [Line Items]            
Fair value assumption, stock price volatility   90.00%        
Fair value assumption, risk-free rate   20.00%